Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized Study of Nivolumab Plus Ipilimumab in Combination With Chemotherapy vs Chemotherapy Alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer
Brief Summary: The purpose of this study is to determine whether Nivolumab, Ipilimumab combined with chemotherapy is more effective than chemotherapy by itself when treating stage IV NSCLC as the first treatment given for the disease


Options:
A: Arm Label: Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin); Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Drug: Carboplatin, Drug: Nab-Paclitaxel | Arm Label: Arm B (Nab-Paclitaxel+Carboplatin); Type: ACTIVE_COMPARATOR; Interventions: Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Drug: Carboplatin, Drug: Nab-Paclitaxel, Drug: Pemetrexed | Intervention Type: DRUG; Name: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody; Assigned to Arm(s): Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin), Arm B (Nab-Paclitaxel+Carboplatin) | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin), Arm B (Nab-Paclitaxel+Carboplatin) | Intervention Type: DRUG; Name: Nab-Paclitaxel; Assigned to Arm(s): Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin), Arm B (Nab-Paclitaxel+Carboplatin) | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): Arm B (Nab-Paclitaxel+Carboplatin)
B: Arm Label: MEDI4736; Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 | Arm Label: PLACEBO; Type: PLACEBO_COMPARATOR; Interventions: Other: PLACEBO | Intervention Type: DRUG; Name: MEDI4736; Assigned to Arm(s): MEDI4736 | Intervention Type: OTHER; Name: PLACEBO; Assigned to Arm(s): PLACEBO
C: Arm Label: Module A; Type: EXPERIMENTAL; Interventions: Biological: Ipilimumab, Biological: Nivolumab, Drug: Carboplatin, Drug: Paclitaxel, Drug: Pemetrexed, Drug: Cisplatin | Arm Label: Module B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Paclitaxel, Drug: Pemetrexed, Drug: Cisplatin | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Module A | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Module A | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Module A, Module B | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Module A, Module B | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): Module A, Module B | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Module A, Module B
D: Arm Label: Pembrolizumab + Chemotherapy Combo; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab, Drug: Paclitaxel, Drug: Nab-paclitaxel, Drug: Carboplatin | Arm Label: Placebo + Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Nab-paclitaxel, Drug: Carboplatin, Drug: Saline placebo for pembrolizumab | Intervention Type: BIOLOGICAL; Name: Pembrolizumab; Assigned to Arm(s): Pembrolizumab + Chemotherapy Combo | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Pembrolizumab + Chemotherapy Combo, Placebo + Chemotherapy | Intervention Type: DRUG; Name: Nab-paclitaxel; Assigned to Arm(s): Pembrolizumab + Chemotherapy Combo, Placebo + Chemotherapy | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Pembrolizumab + Chemotherapy Combo, Placebo + Chemotherapy | Intervention Type: DRUG; Name: Saline placebo for pembrolizumab; Assigned to Arm(s): Placebo + Chemotherapy

Answer: C